Profound depletion of circulating CD19+ B was found in MG patients at both 4 weeks (-98.7% compared to baseline, P < 0.001) and 12 weeks (-98.8% compared to baseline, p < 0.001) after initiating ofatumumab therapy (Figure 4D). The gene discussed is CD19; the disease is myasthenia gravis.